SYGNIS Pharma AG, a specialty pharmaceutical company, engages in the research, development, and marketing of drugs for the treatment of disorders of the central nervous system (CNS). These include stroke or various forms of dementia. AX200 AX200 is a biological molecule, developed by the company for the treatment of neurodegenerative diseases. It is being tested in a 350 patient, multinational phase II efficacy trial. AX200 is an endogenous protein. As part of the body's own protective action the production of AX200 is boosted after brain damage. AX200 displays a multimodal activity: it stops neuronal cell death in the acute phase of the disease while at the same time stimulating the regeneration of the damaged CNS through the stimulation of neurogenesis, as well as arteriogenesis and the reorganisation of neuronal networks. Significant Events The company acquired Amnestix Inc. in 2008. Its business operations focus on the development of novel therapeutics and diagnosis techniques to enhance cognitive and memory functions. History SYGNIS Pharma AG was founded in 1997.
Show more
Heidelberg, DE
Size (employees)
20 (est)
Sygnis Pharma was founded in 1947 and is headquartered in Heidelberg, DE
Report incorrect company information

Sygnis Pharma Office Locations

Sygnis Pharma has an office in Heidelberg
Heidelberg, DE (HQ)
515 Im Neuenheimer Feld
Show all (1)
Report incorrect company information

Sygnis Pharma Financials and Metrics

Summary Metrics

Founding Date

Report incorrect company information

Sygnis Pharma Online and Social Media Presence

Embed Graph
Report incorrect company information

Sygnis Pharma Company Life and Culture

Report incorrect company information